Survival outcomes and time-to-treatment failure in patients with CLPD-NKs and T-LGL. P values presented correspond to the Cox regression between the groups indicated. (A) Comparison of survival outcomes according to the leukemic cell lineage. (B) Comparison of survival outcomes depending on the STAT3 SH2 domain mutational status. (C) Differences in the time-to-treatment failure in patients with or without STAT3 SH2 domain mutation. Time-to-treatment failure was defined as the interval between the start of treatment and the need for initiating a second line of therapy and/or progressive disease (including relapse after remission).